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Abstract
Purpose To review the response and outcomes of 177Lu-
DOTA-octreotate chemoradionuclide therapy (LuTate
PRCRT) in patients with neuroendocrine tumour (NET) ex-
pressing high levels of somatostatin receptors with uncon-
trolled symptoms or disease progression.
Methods A total of 68 patients (39 men; 17 – 76 years of age)
who had completed an induction course of at least three cycles
of LuTate PRCRT between January 2006 and June 2010 were
reviewed. Ten patients were treated for uncontrolled symp-
toms and 58 had disease progression despite conventional
treatment. The majority had four induction LuTate cycles
(median treatment duration 5 months and cumulative activity
31 GBq), and 63 patients had concomitant 5-FU
radiosensitizing infusional chemotherapy. Factors predicting
overall survival were assessed using the log-rank test and Cox
proportional hazards regression.
Results Of those treated for uncontrolled symptoms, 70 %
received benefit maintained for at least 6 months after treat-
ment. Among patients with progressive disease 68 % showed
stabilization or regression on CT, 67 % on molecular imaging
and 56 % biochemically up to 12 months after treatment; 32
patients died. Overall survival rates at 2 and 5 year were
72.1 % and 52.1 %, respectively. Median overall survival
was not estimable at a median follow-up of 60 months (range
5 – 86 months). Nonpancreatic primary sites, dominant liver
metastases, lesion size <5 cm and the use of 5-FU chemother-
apy were statistically significantly associated with objective
response. A disseminated pattern and a high disease burden
(whole-body retention index) were associated with an in-
creased risk of death. Objective biochemical, molecular im-
aging and CT responses were all associated with longer over-
all survival.
Conclusion A high proportion of patients with progressive
NET or uncontrolled symptoms received therapeutic benefit
from LuTate with concomitant 5-FU chemotherapy. The
achievement of objective biochemical, molecular or CT re-
sponses within 12 months was associated with improved
overall survival. Patients with a primary pancreatic site
and larger lesions (>5 cm) appeared to have lower
objective response rates and may need a more aggres-
sive treatment approach.
Keywords 177Lu-Octreotate . Neuroendocrine . 5-FU
chemotherapy . Response . Predictive factors . Survival
Introduction
Neuroendocrine tumours (NET) comprise a heterogeneous
group of neoplasms arising within the diffuse endocrine sys-
temwith variable clinical behaviour depending on the grade of
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tumour. Well-differentiated NETs typically have a low prolif-
erative index, a slow pattern of growth but can metastasize
widely, and secrete hormones resulting in debilitating clinical
symptoms. Poorly-differentiated disease with a high prolifera-
tive index can result in more rapidly progressive disease and
early mortality. Most well-differentiated to moderately-
differentiated tumours retain high expression of somatostatin
receptors (SSTR), a characteristic that can be identified by
molecular imaging and targeted therapeutically by peptide
receptor radionuclide therapy (PRRT). Current guidelines sup-
port the use of PRRT in patients with unresectable grade 1 or 2
NET [1, 2] and high SSTR expression at known tumour sites.
A number of radionuclides have been conjugated to var-
ious somatostatin analogues for PRRT. 90Y emits the most
energetic beta particles and is associated with favourable
responses but moderate toxicity, particularly including renal
impairment [3, 4]. 111In emits the least energetic particles but,
although associated with minimal significant side effects, is
associated with low response rates [5, 6]. More recently,
177Lu-labelled PRRT has been used in a number of interna-
tional centres, and has shown favourable responses with lim-
ited toxicity. Its relatively lower beta particle emission energy
(when compared with 90Y) limits radiation exposure and
toxicity to adjacent normal tissue, whilst still providing the
benefit of the cross-fire effect [5, 7, 8].
Based on the experience in Rotterdam [9], our institution
started using 177Lu-DOTA-octreotate (LuTate) therapy in late
2005 for the treatment of patients with unresectable, symp-
tomatic or progressive NET, not controlled with conventional
therapy. In addition, our PRRT protocol also included the use
of concomitant infusional 5-fluorouracil (5-FU) chemothera-
py as a radiosensitizing agent to potentially further enhance
therapeutic efficacy (peptide receptor chemoradionuclide ther-
apy, PRCRT). This is based on our previous experience that
combining 5-FU and high-activity 111In-octreotide therapy is
safe, with enhanced efficacy particularly with symptomatic
benefit in patients with NET [6]. We have also previously
reported that LuTate is well tolerated by patients who have
previously received 111In-pentreotide therapy, and can be
safely combined with 5-FU chemotherapy without significant
early or late bone marrow or renal toxicities [10]. We review
here the therapeutic response to PRCRTwith LuTate treatment
with medium term to long-term follow-up, and assess any
predictive factors associated with response and overall surviv-
al (OS) in patients with uncontrolled NET.
Patients and methods
Patients
A total of 68 patients (29 women, 39 men; median age
56 years, range 17 – 76 years) with NET who started and
completed an induction course of at least three cycles of
LuTate therapy between January 2006 and June 2010 were
retrospectively reviewed. These patients were followed up to
death or the study close date of 1 June 2013. Median follow-
up, calculated using the reverse censoring method, was
60 months (5 – 86 months).
Eligibility criteria for LuTate therapy included high SSTR-
expressing disease as reflected by positive SSTR scan (111In-
octreotide SPECT/CT or 68Ga-octreotate PET/CT scan) with
an uptake intensity greater than that of normal hepatic paren-
chyma, either uncontrolled symptomatic disease despite max-
imal conventional treatment or progressive disease within the
previous 12 months as reflected by biochemical
(chromogranin A level, CgA level), SSTR or CT imaging
criteria. Patients with a Ki-67 index >10 % or with evidence
of metabolically active disease on the FDG PET/CTscan were
generally offered chemotherapy as first-line therapy, since
these features are associated with higher grade, less well-
differentiated disease and a poorer prognosis [11].
Exclusion criteria for PRRT included spatially discordant
FDG-avid disease showing low or absent SSTR analogue
avidity, decompensated carcinoid heart disease, glomerular
filtration rate <30 ml/min, hypoalbuminaemia (<20 g/L), plate-
let count <50×109/L or pancytopaenia (unless considered to be
reflective of a paraneoplastic process), ECOG performance
score 4, expected survival <3 months, and pregnancy.
All patients were treated on compassionate grounds under a
Special Access Scheme (SAS) which allows treatment of
patients with life-threatening diseases with experimental ther-
apies that have demonstrated efficacy in international trials,
provided that no other proven treatment is available. The use
of SAS provisions was approved by our Institutional Ethics
Committee and all patients provided written informed consent
to undergo treatment and follow-up.
Treatment regimen
177Lu was produced and transported to our institution from
Europe (IDB Holland) as a radiochemical. The peptide
octreotate (Erasmus Medical Centre, Rotterdam, Holland)
was labelled with 177Lu by chelation to a DOTA molecule to
form 177Lu-DOTA-octreotate (LuTate).
Each cycle of LuTate was administered intravenously on an
outpatient day-case basis with premedication including
granisetron and dexamethasone, and with renoprotective ami-
no acid infusion (25 g lysine and 25 g arginine in 1 L normal
saline) commencing 30 min before PRRT and continuing for
3 h thereafter. At 24 h after each treatment, patients underwent
a whole-body posttherapy scan. Awhole-body retention index
based on the percentage of administered dose retained as
shown on the post-LuTate whole-body images after the first
cycle of treatment was calculated by acquiring anterior and
posterior whole-body images using medium energy
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collimation. A reference sample of <5 MBq 177Lu was placed
at the feet of the patient. Regions of interest were drawn
around the body, the reference and a background area outside
the patient, and the geometric mean of the background-
corrected whole-body regions was calculated. The percentage
retention was calculated as the ratio of whole-body counts to
the reference counts multiplied by the ratio of the reference
activity to the decay-corrected administered activity. While
this generally reflects disease burden, it is recognized that
impaired renal function may also influence retention.
The induction treatment regimen typically included
four cycles of LuTate PRCRT 6 – 10 weeks apart. However,
some patients with extensive bone disease received an initial
cycle of 111In-octreotate followed by three LuTate cycles. We
considered that the shorter particle path length of 111In com-
pared to 177Lu may have provided better targeting of small
bony lesions whilst limiting potential toxicity to the surround-
ing marrow. The second to fourth cycles were usually given
with infusional 5-FU chemotherapy (200 mg/m2/24 h)
through a peripherally inserted central catheter as a
radiosensitizing agent, starting approximately 4 days before
the day of PRRT administration, and continued for 3 weeks in
total. Administration was stopped in the event of hand–foot
syndrome or other acute toxicity. The number of cycles was
increased in some patients with a large disease burden and
decreased in patients with a relatively small volume of disease
or comorbidity. Patients who demonstrated disease stabiliza-
tion or improvement were offered ongoing maintenance ther-
apy (usually a single LuTate cycle) every 6 – 18 months,
guided by clinical, imaging and biochemical parameters per-
tinent to their initial presentation, response and comorbidities.
Maintenance treatments were offered to patients with symp-
tomatic or persisting disease with high SSTR expression
(Krenning score 3 or 4, i.e. greater than hepatic uptake or at
least equal to splenic uptake, respectively) who had shown a
previous symptomatic or objective response (stability or im-
provement) to induction LuTate cycles. This was given “pro-
phylactically” every 12 months, or earlier in the event of
biochemical or imaging disease recrudescence.
Follow-up
Patients received follow-up assessments at our institution or
locally (especially for interstate patients) at 3 – 6 months,
6 – 12 months and >12 months after the last induction cycle.
Evaluation included assessment of symptoms, biochemical
markers, molecular imaging (repeating whichever SSTR im-
aging investigation had been performed as the baseline stag-
ing investigation) and CT. Symptomatic benefit was defined
as an improvement in tumour-related symptoms based on the
patient’s subjective report relative to baseline symptoms. A
clinician conducted patient interviews at each follow-up with
direct questioning as to whether tumour-related symptoms had
‘disappeared’ or ‘improved’, or were ‘stable’ or ‘worse’ com-
pared to baseline. Standard international quality-of-life ques-
tionnaires were not routinely used in this cohort, but have
since been implemented.
Biochemical response was documented as the percentage
change using CgA level just prior to the first LuTate cycle as
baseline. Molecular imaging response was defined as stable,
partial response (reduction in intensity or extent or the disap-
pearance of abnormal uptake at some sites of disease), com-
plete response (total disappearance of abnormal uptake by
previous avid lesions) or progressive disease (increase in
intensity or extent of previous abnormal uptake, or develop-
ment of new avid lesions). 111In-Octreotate SPECT or 68Ga-
octreotate PET images were assessed as indicating a response
if they showed a decrease in uptake relative to hepatic and
splenic activity representing a reduction in uptake by one or
more points on the Krenning scale. Metabolic responses were
assessed on the FDG PET images according to the Hicks
criteria as detailed in the PERCIST paper by Wahl et al. [12,
13]. CT response was defined as stable, partial or complete
response, or progression defined by Response Evaluation
Criteria in Solid Tumors (RECIST 1.1). Minor response was
also used to describe smaller size changes not meeting the
criteria for partial response according to RECIST 1.1
(10 – 30 % decrease in maximum diameter of target lesions).
Where available, contrast-enhanced CT images were directly
compared. Otherwise, nonenhanced CT images from the
SPECT or PET components of the study were assessed, using
metabolic uptake as a guide to follow the dominant lesions.
In patients included in the study due to symptomatic dis-
ease, benefit was defined as an improvement in tumour-
related symptoms at 3 – 6 months after induction treatment.
For those included due to previously progressive disease (on
biochemical, molecular imaging or CT criteria), benefit was
defined as stabilization or improvement of disease assessed at
3 – 6 months, and at 6 – 12 months after completion of
induction treatment.
Statistics
The OS curve was estimated for the total cohort of patients
using the Kaplan–Meier product-limit method; point estimates
and corresponding 95 % confidence intervals (95 % CI) were
calculated for annual survival rates. The proportions of pa-
tients achieving biochemical, molecular imaging and CT re-
sponses were calculated separately with corresponding exact
95 % CIs for the subset of patients who were treated for
previously progressive disease.
The following prognostic factors were investigated for
association with both OS and treatment response: patient
age, primary tumour site (pancreatic versus nonpancreatic),
dominant site of disease (liver, bone, nodal or disseminated),
number of tumour lesions (1 – 4, 5 – 20 or >20), size of the
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largest measurable diameter of the dominant lesion (<2 cm,
2 – 5 cm, >5 cm), percentage of whole-body retention, grade
of tumour differentiation (grade 1 Ki-67 index ≤2 %, grade 2
Ki-67 index 3 – 20 %, grade 3 Ki-67 index >20 %), and FDG
avidity (grade 1 uptake less than that of the liver, grade 2
equal to that of the liver, grade 3 slightly greater than that of
the liver, grade 4 markedly greater than that of the liver).
Treatment-related parameters included planned number of
cycles of 177Lu-octreotate (three versus four or more), number
of prior cycles of 111In-octreotide (none, one or more), total
cumulative activity of LuTate (in gigabecquerels), concurrent
use of 5-FU chemotherapy and duration of treatment.
Univariate associations with OS for the total patient cohort
were investigated using Cox proportional hazards regression,
where hazard ratios and associated 95 % CIs are reported.
Tests for the association between response and OS were
performed measuring OS from the start of treatment in order
to facilitate comparison with previous work in this area, and
also from 12 months after the end of treatment to remove bias
associated with having a start date for OS that preceded the
date at which response was measured. Univariate associations
with each of biochemical, functional and CT responses for the
subset of patients treated for previously progressive disease
were investigated using binary logistic regression, where odds
ratios and associated 95 % CIs are reported. Multivariate
analysis was not performed because of the relatively small
number of events and potential codependence of some of the
analysed variables. Rather we sought to establish potential
prognostic factors that might be further assessed in future
prospective studies.
Results
Patient characteristics and treatment parameters
Of the 68 patients, 35 had a nonpancreatic primary, and 33 had
a pancreatic primary tumour. A total of 251 cycles of LuTate
therapy were administered (three cycles given to 26 patients,
four cycles to 38 patients, five cycles to 3 patients, and
six cycles to 1 patient). The median cumulative activity of
the induction courses was 31 GBq (21 – 45.3 GBq) given over
a median of 5 months (3 – 14 months). Concomitant 5-FU
chemotherapy was administered to a majority of the cohort
(63 patients). Five patients did not have concomitant 5-FU:
one had previous 5-FU-related cardiotoxicity, two declined
treatment despite being recommended to have 5-FU, and two
were deemed unfit for chemotherapy. Of note, 27 patients also
had previous high-activity 111In-octreotide treatment. Of these
patients, three had received 111In-octreotide therapy (one to
three cycles) 8 – 36 months before but they were eligible for
subsequent LuTate therapy due to symptomatic or progressive
disease. As part of induction PRCRT, 24 patients received
high-activity 111In-octreotate therapy (20 patients had
one cycle, 4 patients had two cycles) due to the presence of
bony metastases in ten patients, a large tumour burden and
potential flare/toxicity in four patients, and in ten patients for
logistic reasons or limited availability of LuTate, particularly
in the early stages when LuTate therapy first became available
at our institution. Of note, eight patients received chemother-
apy based on a Ki-67 index >10 %, or with concordant highly
FDG avid disease before PRCRT. The majority had
carboplatin/etoposide chemotherapy. One of these patients
achieved a partial metabolic response after chemotherapy,
but the remaining patients had either no response (six patients)
or progression (one patient) on both molecular imaging and
RECISTassessment. After subsequent LuTate induction treat-
ment, the patient who progressed on chemotherapy continued
to do so, suggesting refractory disease. However, all the seven
other patients demonstrated a partial molecular imaging re-
sponse and four of these patients also achieved a partial
morphological response, suggesting that previous chemother-
apy had minimal prognostic influence in these patients.
Of the 68 patients, 10 started treatment due to uncontrolled
symptoms and 58 started treatment due to disease progression.
The patient characteristics are summarized in Table 1.
Overall survival
Of the 68 patients, 32 died before the close date. The observed
annual OS rates were as follows: 1 year 88 % (95 % CI
78 – 94 %), 2 years 72 % (95 % CI 60 – 81 %), 3 years
63 % (95 % CI 51 – 74 %), 4 years 56 % (95 % CI
44 – 67 %), and 5 years 52 % (95 % CI 40 – 64 %).
Median OS was not estimable despite a median follow-
up period of 60 months (Fig. 1).
Overall response at 3 – 6 months after treatment
Uncontrolled symptoms Of the 68 patients, 10 were treated for
tumour-related symptomatic disease. At 3 months after treat-
ment, nine patients reported symptomatic response. At
6 months, seven patients (70 %) reported continuing benefit
from treatment. However, two patients had redeveloped in-
creasing pain related to further progressive disease despite
treatment, and one patient reported worsening carcinoid hor-
monal symptoms despite a good initial symptomatic response.
Most patients reported improved symptomswith reduced flush-
ing, diarrhoea, soft-tissue and bone pain as well as weight gain.
Previous progressive disease Of the 68 patients, 58 were
treated for disease progression. A high proportion of these
patients (44, 76 %) received benefit from PRRT resulting in
either stabilization or improvement on imaging of previously
progressive disease. However, one patient died at 8 months
despite a good early response. Of the 58 patients, 14 (24 %)
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Table 1 Patient baseline characteristics and treatment-related parameters for the total cohort of 68 patients
Characteristic Disease progression (N=58) Uncontrolled symptoms (N=10) All patients (N=68)
Age at first treatment (years)
Median 55.5 57.5 56.0
Range 17 – 76 42 – 70 17 – 76
Primary site, N (%)
Pancreatic NET 25 (43) 4 (40) 29 (43)
Small bowel 11 (19) 1 (10) 12 (18)
Large bowel 7 (12) 0 (0) 7 (10)
Lung 3 (5) 0 (0) 3 (4)
Gastrinoma 3 (5) 0 (0) 3 (4)
Glucagonoma 1 (2) 0 (0) 1 (1)
Thymus 0 (0) 1 (1) 1 (1)
Unknown 8 (14) 4 (40) 12 (18)
Nonpancreatic NET 29 (50) 6 (60) 35 (51)
Pancreatic NET 29 (50) 4 (40) 33 (49)
Dominant site of disease, N (%)
Liver 36 (62) 6 (60) 42 (62)
Bone 1 (2) 0 (0) 1 (1)
Primary 4 (7) 1 (10) 5 (7)
Nodal 2 (3) 0 (0) 2 (3)
Disseminated 15 (26) 3 (30) 18 (26)
Number of lesions, N (%)
1 – 4 4 (7) 2 (20) 6 (9)
5 – 20 36 (62) 6 (60) 42 (62)
>20 18 (31) 2 (20) 20 (29)
Size of dominant lesion (cm), N (%)
<2 1 (2) 0 (0) 1 (1)
2 – 5 32 (55) 7 (70) 39 (57)
>5 24 (41) 3 (30) 27 (40)
Unknown 1 (2) 0 (0) 1 (1)
Whole-body retention (%)
Median 18.1 16.0
Range 5.8 – 40.9 5.6 – 40.9
Grade of tumour differentiation, N (%)
1 (Ki-67 index<3 %) 7 (12) 2 (20) 9 (13)
2 (Ki-67 index 3 – 20 %) 26 (45) 4 (40) 30 (44)
3 (Ki-67 index>20 %) 0 (0) 0 (0) 0 (0)
Unknown 25 (43) 4 (40) 29 (43)
FDG avidity grade before treatment, N (%)
0 (no uptake) 2 (3) 0 (0) 2 (3)
1 (< liver) 0 (0) 0 (0) 0 (0)
2 (= liver) 1 (2) 0 (0) 1 (1)
3 (slightly > liver) 11 (19) 2 (20) 13 (19)
4 (markedly > liver) 10 (17) 1 (10) 11 (16)
Unknown 34 (59) 7 (70) 41 (60)
Cumulative LuTate activity (GBq)
Median 30.9 31.0
Range 21.0 – 45.3 21.0 – 45.3
Treatment duration (weeks)
Median 20.0 21.0
Range 12 – 62 12 – 62
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had no clear benefit from treatment with early disease pro-
gression, and 12 of these patients died within 12 months of the
last treatment.
Objective response at 6 – 12months after treatment in patients
with previous progressive disease
Biochemical (CgA) response Of the 58 patients with pro-
gressive disease, 2 had no follow-up CgA results avail-
able, and 6 had a very low baseline level (<30 U/L);
therefore these patients were excluded. Hence, 50 pa-
tients were for included in the analysis, and 28 of these
(56 %) achieved a biochemical response as defined as a
decrease from the baseline level (Fig. 2).Of these, 13/28
had >50 % reduction from baseline, 9/28 had
25 – 50 % reduction from baseline, and 6/28 had
<25 % reduction from baseline. 9/50 patients (18 %)
had documented CgA progression over baseline level.
However, three of these patients only had a mild
relative increase of <25 % over baseline, and whilst
counted as progression, may have represented a slowing
of disease.
Molecular imaging response One of 58 patients had no avail-
able follow-up; hence 57 patients were evaluated. Overall 38
of 57 patients (67 %) had benefit (95 % CI 53 – 79 %): 13 of
57 (23 %) had stabilization of previously progressive disease,
and 25 of 57 (44 %) achieved a partial response (Fig. 2). Only
3 of 57 patients had progressive disease, and 3 had a mixed
response but were still assessable at 12 months.
CT response Two of 58 patients had no CT-evaluable lesions;
hence 56 patients were evaluated. Overall 38 of 56 patients
(68 %) had a response (95 % CI 54 – 80 %): 16 of 56 (29 %)
had stable disease, 17 of 56 (30 %) had a partial response, and
5 of 56 (9 %) had a minor response (Fig. 2). A further 4 of 56
patients had disease progression and 1 had a mixed response.
Of these patients, 13 died of disease progression within
12 months. Of the 68 patients, 11 had a further response
beyond 12 months after the last induction treatment cycle,
and before any maintenance PRRT. One of these patients had
achieved a complete molecular imaging and CT response at
3 years after the last induction cycle. Another patient had the
tumour completely resected as a result of a significant re-
sponse to induction treatment.
Of the 68 patients, 44 (68 %) received subsequent
LuTate maintenance therapy: 9 patients had one cycle,
16 patients two cycles, 9 patients three cycles, 5 pa-
tients four cycles, 2 patients five cycles, and 3 patients
six cycles. Of these patients, 17 had no documented
disease progression from after induction treatment to
the time of this report, but were considered at high
risk of progression. Eight patients with subsequent
progression after initial induction LuTate treatment
had achieved further stabilization or regression of dis-
ease with maintenance therapy. Despite an initial
Fig. 1 Estimated Kaplan–Meier curve for OS from the start of the first
cycle of treatment
Fig. 2 Biochemical, molecular
imaging and CT responses 6 –
12 months after the last induction
cycle of LuTate therapy in
patients with previously
progressive disease. The overall
biochemical, molecular imaging
and CT response rates were 56 %,
67 % and 68 %, respectively
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favourable response to induction cycles, 19 patients
developed subsequent disease progression despite fur-
ther maintenance treatments.
Prognostic/predictive factors associated with overall survival
and objective response
Overall survival Patients with a disseminated pattern of dis-
ease had a significantly increased risk of death relative to
patients in whom the dominant site of disease was the liver.
For every unit increase in percentage of whole-body retention,
the risk of death increased providing potential prognostic
stratification at the commencement of treatment. A biochem-
ical, functional molecular imaging and CT imaging response
at 6 – 12 months was also significantly associated with im-
proved OS. Imaging responses (functional imaging and CT)
yield strongly significant results when measured from 6 to
12 months after treatment (Fig. 3, Table 2).
Biochemical response Patients with a primary pancreatic
NET (compared to nonpancreatic), a disseminated pattern,
and the dominant lesion >5 cm in size were statistically
significantly less likely to achieve a biochemical re-
sponse (Table 3).
Functional imaging response Patients with a primary pancre-
atic NETwere significantly less likely to achieve a molecular
imaging response, while patients who underwent concurrent
5-FU chemotherapy were more likely to achieve a molecular
imaging response even though the number of patients not
receiving chemotherapy (n=5) was low (Table 3).
CT response Significant univariate associations were found
for primary tumour site, size of dominant lesion <5 cm and
concurrent use of 5-FU chemotherapy (Table 3 and
Supplementary table online). A subgroup of patients who
had partial and minor CT response (excluding stable disease)
were also analysed, and significant positive associations were
found for the number of tumour lesions (four or fewer),
number of LuTate cycles (four or more), total cumulative
activity, and concurrent 5-FU chemotherapy.
Discussion
LuTate PRRT has been used to treat patients with inoperable
metastatic NET with high SSTR expression, but comparison
of toxicity and outcomes have often been difficult due to
heterogeneous patient populations, variable study designs,
and different response assessments. Importantly, some studies
showing high rates of stable disease have not required disease
progression prior to PRRT therapy. In contrast to the other
published series, however, our study had a long follow-up
assessment for both objective response and OS, comprising a
balanced proportion of primary tumour site (pancreatic versus
nonpancreatic), and is, we believe, the largest study utilizing
LuTate with 5-FU chemoradionuclide therapy. The use of
PRCRT based on compassionate grounds involved applica-
tion of strict inclusion criteria limiting treatment to patients
with symptomatic or progressive disease uncontrolled by
conventional therapy. In fact, only a minority of our cohort
were treated for uncontrolled symptoms, possibly because of
an aggressive policy of dose escalation of somatostatin ana-
logues if tolerated by the patient. Despite this approach, up to
70 % of our cohort reported improvement beyond 6 months
after PRCRT. This also supports the findings of another study
including 50 patients evaluated for quality of life that showed
a significant improvement in global health status at 6 weeks
after the last 177Lu-octreotate cycle [14]. A study in 265
patients by Khan et al. also showed an improvement in quality
of life and Karnofsky performance score [15]. The majority of
our patients were treated for disease progression within
12 months, and this possibly explains the significant propor-
tion of grade 2 tumours in our series (Table 4).
Among the majority of this cohort who were treated for
progressive disease, a high proportion (76 %) received benefit
based on disease stabilization or regression at the early
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Fig. 3 Estimated Kaplan–Meier OS curve associated with a biochemical, b CT, and c molecular imaging responses from the start of the first cycle of
treatment
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treatment, and a high percentage continued to demonstrate
benefit at 6 – 12months after treatment. Given that the median
duration of induction treatment was 5 months, the initial
response assessment was typically 8 – 12 months following
the start of treatment, an interval over which most patients had
previously progressed. Both CT and functional molecular
imaging showed a similar rate of disease stabilization or
regression (68 % versus 67 %), although molecular imaging
was more often associated with regression (44 % versus 29%;
all partial response). Of note, 9 % of patients also had a minor
CT response. One patient who responded significantly on both
CT and functional imaging underwent complete resection of
residual disease, which had initially been assessed to be inop-
erable, supporting the role of PRCRT. Thus, PRCRT may
render a small proportion of inoperable NET resectable [16].
In addition, 16 % of patients also demonstrated further re-
sponse beyond 12 months after completion of induction treat-
ment, including one patient who achieved a complete re-
sponse on molecular imaging and CT criteria at 3 years after
the induction cycle without any additional therapy, suggesting
an ongoing and potentially delayed therapeutic effect in some
patients (Fig. 4). This phenomenon has also been described by
Kwekkeboom et al. [9]. The overall findings are at least
comparable to those of other series with objective partial
response rates of 17 – 28 % [17–20]. The largest series
showed a CT partial response of 28 % and a minor response
of 16 % [9]. However, such a high rate of response including
Table 2 Factors associated with overall survival
Factor Hazard ratio 95 % CI P value
Dominant site of disease
Liver 0.03
Bone NE –
Primary 0.50 0.07 – 3.74
Nodal 1.33 0.18 – 9.99
Disseminated 2.78 1.34 – 5.74
Whole-body retention
≤16 %
>16 % 2.07 1.02 – 4.21 0.04
As continuous variable 1.06 1.02 – 1.10 0.002
Response measured from start of treatment
Biochemical response 0.20 0.09 – 0.45 <0.001
Molecular imaging response 0.08 0.04 – 0.19 <0.001
CT response 0.06 0.03 – 0.14 <0.001
Response measured from 6 to 12 months after treatment response
assessment
Biochemical response 0.59 0.18 – 1.9 0.382
Molecular imaging response 0.2 0.06 – 0.64 0.003
CT response 0.13 0.04 – 0.2 <0.01
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disease stabilization in this cohort is a particularly en-
couraging result given that our patients were treated in
the setting of progressive disease with otherwise limited
therapeutic options.
Several factors were found to be significantly associated
with an objective response. These included primary tumour
site, dominant site of disease, size of dominant lesion, and the
use of concurrent 5-FU chemotherapy. Although there was no
statistically significant association with OS, patients with a
nonpancreatic primary tumour seemed more likely to have
biochemical, molecular imaging and CT responses, suggest-
ing that disease from a primary pancreatic tumour is more
resistant and difficult to control, and hence a more aggressive
therapeutic approach/regimen may be warranted. Patients
with dominant liver disease compared to those with a dissem-
inated pattern are more likely to have biochemical response.
Patients with a dominant lesion size of <5 cm are significantly
more likely to achieve molecular imaging and CT response.
Therefore, using more powerful radiopharmaceuticals such as
90Y, which has a longer beta radiation path length, may be
more efficacious in treating larger lesions. Although few
patients did not receive 5-FU chemotherapy, the use of 5-FU
chemotherapy was found to be strongly associated with mo-
lecular imaging and CT response in this cohort. Favourable
response rates without associated increases in toxicity have
also been reported from a recent study using LuTate combined
with capecitabine, the oral form of 5-FU chemotherapy [19].
A previous study from our institution showed no significant
Fig. 4 A 63-year-old patient with
previously resected primary
pancreatic NET referred for
LuTate therapy due to progressive




Centre Fused transaxial SPECT/
CT images. Bottom Contrast-
enhanced CT images. a After the
first cycle of LuTate therapy at
treatment baseline, the images
show high SSTR-expressing liver
metastases (red arrow most
dominant lesion). b Complete
scintigraphic and anatomical CT
response to treatment
approximately 3 years after
induction LuTate therapy without
any intervening treatments and
despite only a partial early
response. This patient remained
disease-free at the time of this
report
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additional toxicity when 5-FU was given with high-activity
111In-octreotide therapy [6] and in a patient population over-
lapping with that of the current study also showed that admin-
istration of LuTate after previous high-dose 111In-octreotide
therapy is safe [10].
Of interest, factors associatedwith tumour shrinkage onCT
included fewer lesions, more LuTate cycles, and higher total
cumulative activity. This suggests a possible dose–response
effect and warrants investigation of personalized dosimetry.
Other prognostic factors for predicting tumour remission ob-
served in previous studies include high uptake on diagnostic
Octreoscan and a Karnofsky performance score of >70 [9].
Both these factors tend to be associated with lower tumour
burden. Another study also suggested that a low tumour
burden and a low proliferation index are prognostic factors
for long progression-free survival [21].
One of the major advantages of this study was the long
follow-up, allowing determination of OS rates at 2 and 5 years
(which were 72 % and 52 %, respectively), with median
survival not estimable despite this. Our results are at least
comparable, if not superior, to those of the largest published
series which showed a median OS of 46 months from the start
of treatment [9]. Patients with a disseminated pattern and large
disease burden had a significantly increased risk of death.
Most importantly, biochemical, molecular or CT stabilization
or regression within 12 months was significantly associated
with longer OS. Our results support those of a prior study
indicating that tumour shrinkage may not be related to surviv-
al [20] and also indicate that molecular imaging response
provides a potential imaging biomarker of response given its
association with improved survival. The predictive value of
molecular imaging response was also maintained when sur-
vival was estimated from the date of the scan. It may therefore
provide an alternative assessment tool to CT anatomical re-
sponse. CT responses using RECIST criteria alone may not
accurately assess NET liver lesions in the posttreatment set-
ting due to variable contrast enhancement and necrosis leading
to pseudoprogression. Having molecular imaging to
characterize lesions is pivotal to selection of target
lesions and their follow-up.
Our regular maintenance treatment protocol may have
contributed to the overall good survival. The majority of
patients remained stable without progression on maintenance
suggesting a tumoristatic effect. However, further stabilization
or regression was also seen in patients with subsequent pro-
gression after an initial response (Fig. 5). Two studies have
also shown that the use of LuTate as salvage treatment is
effective and safe in patients with progressive disease after
initial benefit from induction treatment [22, 23].
This study was designed to assess the predictors of re-
sponse and long-term survival of progressive NET treated
with PRCRT; hence toxicity was not evaluated in this cohort
but was the subject of previous studies in overlapping patient
cohorts. We have previously reported the lack of significant
short-term nephrotoxicity or myelotoxicity of LuTate PRCRT
[10]. Similarly, we also recently reported the lack of long-term
nephrotoxicity with LuTate PRCRT [24]. One patient in this
cohort with progressive NET who received a total of
seven cycles of PRCRT (cumulative activity 56.4 GBq) over
4 years but in the setting of previous chemotherapy treatments
was subsequently diagnosed with acute myeloid leukaemia
with underlying myelodysplastic changes despite a good ini-
tial response from PRCRT. Another patient was diagnosed
with myelodysplastic syndrome (MDS) after five cycles of
PRCRT (37.9 GBq), but this was considered not to be
treatment-related given preexisting thrombocytopaenia at the
time of the first PRRT and with a translocation not typical of
radiation-induced MDS. Serious late adverse events probably
caused by PRRT are rare, with MDS occurring in approxi-
mately 1 % of patients in the largest series [9].
This analysis did, however, have recognized limitations
related to the retrospective nature of the study that potentially
confounded response and prognostic assessment. Being a
compassionate treatment, the treatment strategy was person-
alized rather than protocol-driven. Indeed, there has been an
evolution in our treatment approach over the past 5 years.
Towards the end of the period covered by this cohort, we
began to treat more rapidly progressive disease more using
higher administered activities, decreased intervals between
cycles, or additional induction LuTate cycles. We have also
attempted to deliver higher cumulative activities to patients
with larger disease burdens. Whether these changes will im-
prove patient outcomes requires further assessment. However,
there was no significant association between the year of
starting PRCRT and OS. Further, since the Ki-67 proliferative
index was not routinely determined particularly in patients
who were recruited early in this cohort, incomplete data
restricted assessment of this parameter as a prognostic factor.
Finally, many patients were comanaged by clinicians outside
our own institution, and a uniform follow-up approach was
logistically challenging. To prevent unnecessary duplication
of diagnostic CT performed elsewhere, triple phase CT was
not routinely repeated but was performed if lesions could not
be adequately assessed by non-contrast CT guided by the
functional imaging data. Almost all patients regularly returned
to our institution for molecular imaging follow-up with
SPECT/CT or PET/CT enabling adequate comparative
RECIST measurements.
Given the overall encouraging results in terms of response
and OS in our study and other previous studies, LuTate
therapy can be recommended for patients with symptomatic
or progressive grade 1 or grade 2 NETwho have failed or are
unsuitable for alternative therapies. Combining with 5-FU
chemotherapy whenever clinically appropriate may also pro-
vide synergistic benefit. With increasing recognition of the
heterogeneous phenotypes of NET and expanding
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multimodality treatment options, we believe that a more indi-
vidualized approach should be adopted to further maximize
therapeutic benefit. In particular, our results suggest that pa-
tients with metastatic disease from primary pancreatic tumour
and those with larger dominant lesion size (>5 cm) may
require a more aggressive treatment regimen. Options would
include combining LuTate with 90Y PRRT [25–27]. Surgical
debulking following response from induction PRCRT could
be considered where appropriate. Based on our recent study
suggesting that tumour sequestration is a major factor leading
to a ‘sink effect’ that decreases activity concentration in
healthy organs such as the kidney [28], we hypothesize that
giving higher administered activity per cycle particularly in
those with larger disease burden may allow greater radiation
dose to individual lesions and increased therapeutic index.
Given the favourable overall results in this series and recent
analysis of our results in patients with a poorer prognosis
based on FDG PET/CT (manuscript in preparation), we have
increasingly used PRCRT as first-line treatment in patients
with progressive tumours who remain amenable to PRCRT as
a result of adequate SSTR expression at all known sites of
disease irrespective of Ki-67 (including grade 2 NET and
grade 3 neuroendocrine carcinoma). In addition, combining
LuTate with other concomitant chemotherapy agents to fur-
ther increase efficacy should also be considered. Recent stud-
ies have shown that capecitabine and temozolomide are highly
active and well tolerated in well-differentiated metastatic pan-
creatic NET [29, 30]. A recent study combining this regimen
with LuTate has shown promising results [31], and therefore
may be considered in patients with metastatic grade 2 NET or
grade 3 neuroendocrine carcinoma of the pancreas.
Conclusion
This study suggests that LuTate PRCRT results in therapeutic
benefit in a high proportion of patients with uncontrolled
symptoms or previously progressive NET with high SSTR
expression despite conventional treatment. Patients achieving
objective biochemical, molecular imaging or CT responses
within 12 months, and those with a limited and lower disease
Fig. 5 A 72-year-old patient with a primary of the pancreatic tail with
liver metastases (grade 2 tumour, Ki-67 index 10 – 20%) and progressive
disease despite carboplatin/etoposide chemotherapy. a After the first
cycle of LuTate, whole-body planar images show dominant high uptake
in multiple liver lesions. b 111In-Octreotate whole-body planar image
15 months after completion of induction therapy shows a significant
scintigraphic and CT response (latter not shown), with significant reduc-
tion of CgA levels from baseline (460 to 64 U/L). c Restaging 111In-
Octreotate planar image at 27months after completion shows progression
of liver metastases and new small volume skeletal metastases (ribs, pelvis
red arrows). These imaging findings were accompanied by symptoms of
lethargy and weight loss. Given a previous favourable response to ther-
apy, a further cycle of maintenance LuTate treatment (with 5-FU chemo-
therapy) was given. d Restaging 111In-octreotate images 14 months after
maintenance therapy show a dramatic further response to treatment with
marked regression of liver disease and resolution of multifocal bone
disease. This was accompanied by significant improvement in symptoms
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burden tended to show a longer OS. Patients with a primary
pancreatic tumour, larger lesions and higher disease burden
may need a more aggressive treatment approach.
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